Home » Authors » Mark McCarty

Articles by Mark McCarty

AMO, Intralase merger seen as complementary in $808M deal

Jan. 9, 2007

By Mark McCarty

Thermal meter gives diabetics chance to stave off foot ulcers

Jan. 8, 2007

By Mark McCarty

Studies cast doubt on patient benefits and impact of P4P

Jan. 5, 2007

By Mark McCarty

‘Watchful waiting’ downgraded clinically, upgraded financially

Jan. 4, 2007

By Mark McCarty

CBO sets doc fix tab at $3.1B, but SGR cuts resume in ‘09

Jan. 4, 2007

By Mark McCarty

Canadian journal report charge: Company-sponsored DES trials feature ‘lower study quality’

Jan. 3, 2007

By Mark McCarty

'Watchful waiting' downgraded clinically, upgraded financially

Jan. 2, 2007

By Mark McCarty

Dispute panel wants more CorCap data

Jan. 1, 2007

By Mark McCarty

No changes foreseen in FDA's regulation of DES technology

Jan. 1, 2007

By Mark McCarty

Few surprises, little new FDA action seen for addressing DES

Jan. 1, 2007

By Mark McCarty

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for April 9, 2025.
FDA clears path for Boston Sci’s Bolt IVL to challenge J&J’s Shockwave
BioWorld MedTech
Boston Scientific Corp.’s up to $664 million acquisition of Bolt Medical Inc. closed just days after Bolt secured U.S. FDA 520(k) clearance for its intravascular...
Biopharma exempt from US reciprocal tariffs, but not untouched
BioWorld
At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...
ADPD 2025: Novel treatment modalities in neurodegenerative disorders
BioWorld Science
The current treatment strategies for neurodegenerative diseases focus on targeting Aβ in Alzheimer’s disease (AD), α-synuclein aggregates in Parkinson’s disease...